Loading

Crizotinib as the Standard of Care in Advanced…

November 21, 2018 Responses to crizotinib in ALK+ inflammatory myofibroblastic tumors were consistent with responses in ALK+ NSCLC, according to presenter Dr Schöffski. Patrick Schöffski, MD, of the Katholieke Universiteit Leuven in Belgium, presented data…

2018 World Conference on Lung Cancer: 8 Key…

November 21, 2018 In a phase 3 trial, durvalumab was found to prolong survival in patients with stage III NSCLC. Lung Cancer Awareness Month is an opportunity to focus on promising research in the field.…

BRAF Splice Variants May Mediate Resistance to RAF…

November 21, 2018 The discovery could provide opportunities to target resistance driven by aberrantly spliced forms of BRAF V600E. A new study has demonstrated that the phosphobinding site serine 729 mediates enhanced association between BRAF…